A combinatorial therapy including multivesicular liposome technology, designed to supply arginine to melanoma tumors, and selective suppression of the CAT2 transporter, leads to arginine starvation of tumor cells but promotes the infiltration of CD8+ T cells in the TME (100). This evidence concerns the gene CD8A and melanoma.